# Stefan Luzi

> Stefan Luzi is a Series B investor at Gilde Healthcare backing Biopharma and Therapeutics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners)
- Location: Utrecht, The Netherlands
- Total investments: 2
- Last investment: Jul 2024
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/stefanluzi
- Website: http://camswiss.soc.srcf.net/

Stefan Luzi is a Series B investor at Gilde Healthcare in Utrecht focused on Biopharma and Therapeutics. Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on the generation and assessment of investment cases in the biopharm, medtech, diagnostics and digital health sectors and supports transaction execution and fund management.Prior to joining Gilde, Stefan worked at Merck KGaA for two years. As part of the Global Graduate Program hecompleted several international assignments, most notably with the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions.Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK) where he developed a bicyclic peptide based drug discovery platform.He is a Swiss citizen based in Gilde’s Utrecht office.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series D | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 50% |
| United Kingdom | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CatalYm | Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $150M | Series D | Jul 16, 2024 |  |
| Amphista Therapeutics | Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins. | $53M | Series B | Mar 17, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 2 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 2 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 1 deal together
- [BioMotiv](https://shizune.co/investors/profile/biomotiv) — VC Fund, 1 deal together
- [Bioqube Ventures](https://shizune.co/investors/profile/bioqube-ventures) — VC Fund, 1 deal together
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 1 deal together

## About Gilde Healthcare

VC Fund · Utrecht, The Netherlands

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

5 contacts available at Gilde Healthcare.

| Name | Title | Profile |
| --- | --- | --- |
| Edwin Graaf | Managing Partner | https://shizune.co/investors/profile/edwin-de-graaf |
| Joep Muijrers | General Partner | https://shizune.co/investors/profile/joep-muijrers |
| Pieter van der Meer | Managing Partner & Founder | https://shizune.co/investors/profile/pieter-van-der-meer |
| Stefan Luzi | Partner | https://shizune.co/investors/profile/stefan-luzi |
| Arthur Franken | Partner | https://shizune.co/investors/profile/arthur-franken |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Stefan Luzi invest in?

Stefan Luzi invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series B and Series D stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Stefan Luzi last invest?

The most recent investment recorded for Stefan Luzi closed in Jul 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co